Equity Profile

PCVX

Vaxcyte, Inc.

Health CareBiotechnology$8.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases. With a market cap of $8 billion, it operates in the health care sector, which is increasingly important as global health challenges continue to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, missing estimates by nearly 24%. Despite the miss, the stock rose by 2.62% the next day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Vaxcyte's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can improve its financial performance.

Bull Case

If Vaxcyte can show significant progress in its vaccine development and improve its EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company continues to report larger-than-expected losses and lacks clear guidance on future revenue, it may face downward pressure on its stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Vaxcyte's vaccine candidates and their expected timelines?

Investors will closely monitor any updates on vaccine development, as this could significantly impact future revenue and stock performance.

How does Vaxcyte plan to address its ongoing losses and improve profitability?

Management's strategy for improving financial performance will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte to pivot its strategy and achieve better-than-expected results in vaccine development.

Supporting Evidence

The options market is pricing in a significant move of 22.18%, suggesting traders expect volatility that may not align with current consensus.

Vaxcyte has a history of surprising investors, as evidenced by its mixed earnings reactions despite misses.

Key Risk

If Vaxcyte can demonstrate a clear path to reducing losses and advancing its vaccine candidates, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Vaxcyte's ability to turn its financial performance around amidst ongoing development challenges.

Bull Confirmed If

A reduction in EPS losses to below -$2.00 would indicate positive momentum and investor confidence.

Bear Confirmed If

Continued losses exceeding -$2.50 per share would confirm bearish sentiment and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations and raises guidance, history suggests the stock could see a modest increase, averaging around +2.62% on the next trading day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

Should Vaxcyte miss expectations again, history indicates a potential decline, with average moves down around -0.06% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for vaccine candidates and any recent trial results.
2Management's strategy for reducing losses and improving profitability.
3Any partnerships or collaborations that could enhance Vaxcyte's market position.
4Insights into market demand for Vaxcyte's vaccines and competitive landscape.
5Guidance on future revenue expectations and operational plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, missing estimates by nearly 24%. Despite the miss, the stock rose by 2.62% the next day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Vaxcyte's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can improve its financial performance.

Bull Case

If Vaxcyte can show significant progress in its vaccine development and improve its EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company continues to report larger-than-expected losses and lacks clear guidance on future revenue, it may face downward pressure on its stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Vaxcyte's vaccine candidates and their expected timelines?

Investors will closely monitor any updates on vaccine development, as this could significantly impact future revenue and stock performance.

How does Vaxcyte plan to address its ongoing losses and improve profitability?

Management's strategy for improving financial performance will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte to pivot its strategy and achieve better-than-expected results in vaccine development.

Supporting Evidence

The options market is pricing in a significant move of 22.18%, suggesting traders expect volatility that may not align with current consensus.

Vaxcyte has a history of surprising investors, as evidenced by its mixed earnings reactions despite misses.

Key Risk

If Vaxcyte can demonstrate a clear path to reducing losses and advancing its vaccine candidates, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Vaxcyte's ability to turn its financial performance around amidst ongoing development challenges.

Bull Confirmed If

A reduction in EPS losses to below -$2.00 would indicate positive momentum and investor confidence.

Bear Confirmed If

Continued losses exceeding -$2.50 per share would confirm bearish sentiment and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations and raises guidance, history suggests the stock could see a modest increase, averaging around +2.62% on the next trading day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

Should Vaxcyte miss expectations again, history indicates a potential decline, with average moves down around -0.06% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for vaccine candidates and any recent trial results.
2Management's strategy for reducing losses and improving profitability.
3Any partnerships or collaborations that could enhance Vaxcyte's market position.
4Insights into market demand for Vaxcyte's vaccines and competitive landscape.
5Guidance on future revenue expectations and operational plans.